Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
CSPC Pharmaceutical Group ( (HK:1093) ) has issued an update.
CSPC Pharmaceutical Group has obtained drug registration approval in China for its 4mg budesonide enteric-coated capsules, a corticosteroid-based therapy designed for adult patients with primary immunoglobulin A nephropathy at risk of disease progression. The product uses dual delayed-release and sustained-release technology to deliver pathogenesis-targeted treatment with low systemic exposure and a favorable safety profile.
Management said the new approval will broaden the company’s offerings in nephrology and bolster its competitive position in this specialty area. By adding a targeted therapy for IgA nephropathy, CSPC deepens its presence in complex chronic kidney diseases, potentially enhancing its long-term growth prospects in a high-need segment of the renal therapeutics market.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$13.05 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group is a Hong Kong–incorporated pharmaceutical company focused on developing and manufacturing innovative and generic medicines. The group targets key therapeutic areas, including nephrology, and leverages advanced formulation technologies to expand its portfolio and strengthen its presence in the Chinese healthcare market.
Average Trading Volume: 86,548,284
Technical Sentiment Signal: Buy
Current Market Cap: HK$85.01B
For detailed information about 1093 stock, go to TipRanks’ Stock Analysis page.